R Squared Ltd Acquires New Shares in BioAge Labs, Inc. $BIOA

R Squared Ltd bought a new position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) during the third quarter, HoldingsChannel.com reports. The firm bought 26,159 shares of the company’s stock, valued at approximately $154,000.

A number of other hedge funds have also made changes to their positions in the company. Vontobel Holding Ltd. raised its stake in shares of BioAge Labs by 36.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after buying an additional 4,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs in the second quarter valued at about $27,000. Intech Investment Management LLC acquired a new stake in shares of BioAge Labs in the second quarter valued at approximately $60,000. Finally, Walleye Capital LLC purchased a new position in shares of BioAge Labs during the 2nd quarter worth approximately $64,000.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BIOA shares. Morgan Stanley set a $23.00 target price on BioAge Labs in a research note on Wednesday, February 4th. Piper Sandler initiated coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Oppenheimer began coverage on shares of BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.67.

BioAge Labs Trading Down 0.2%

BioAge Labs stock opened at $22.27 on Monday. The stock has a fifty day moving average price of $18.29 and a 200 day moving average price of $11.00. BioAge Labs, Inc. has a 52 week low of $2.88 and a 52 week high of $24.00. The firm has a market capitalization of $798.49 million, a P/E ratio of -14.65 and a beta of 1.42.

Insider Activity

In other news, CEO Kristen Fortney sold 233,107 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the transaction, the chief executive officer directly owned 976,949 shares in the company, valued at $17,702,315.88. This represents a 19.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the sale, the chief financial officer directly owned 22,408 shares in the company, valued at $441,437.60. This represents a 54.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 354,437 shares of company stock valued at $5,813,228 in the last 90 days. 20.82% of the stock is currently owned by insiders.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.